New Frontiers in ER+ Breast Cancer: A Field in Transformation

Published on Makuku Global Research | June 2026

Estrogen receptor-positive (ER+) breast cancer is the most common subtype of the disease, accounting for roughly 70–80% of all diagnoses. For decades, the treatment paradigm was relatively stable — endocrine therapy, then CDK4/6 inhibitors, then the inevitable reckoning with resistance. But in the past 18 months, that paradigm has cracked open. A wave of novel drug classes, precision biomarker strategies, and regulatory milestones is reshaping what it means to treat ER+ breast cancer in 2026. This article breaks down the most consequential developments — and what they mean for patients and clinicians.

The Resistance Problem: Why ESR1 Mutations Changed Everything

To understand where the field is going, you have to understand why it needed to move. CDK4/6 inhibitors — palbociclib, ribociclib, and abemaciclib — transformed first-line treatment for advanced ER+/HER2-negative breast cancer when paired with endocrine therapy. But cancer adapts. Under the selective pressure of long-term endocrine therapy, tumor cells frequently develop mutations in the ESR1 gene, which encodes the estrogen receptor itself. These mutations allow the receptor to stay constitutively active even in the absence of estrogen, rendering aromatase inhibitors largely ineffective.

ESR1 mutations are now detected in approximately 40–50% of patients whose disease has progressed on endocrine therapy and a CDK4/6 inhibitor — a staggeringly common mechanism of acquired resistance. This has made ESR1 mutation status a defining biomarker in modern ER+ breast cancer management, and it has driven the development of an entirely new class of drugs.

The PROTAC Revolution: Vepdegestrant and the First of Its Kind

The most headline-grabbing development of 2026 arrived on May 1st: the FDA approved vepdegestrant (Veppanu), developed by Arvinas and Pfizer, making it the first-ever FDA-approved PROTAC (PROteolysis-TArgeting Chimera) therapy in oncology — a genuinely historic moment.

PROTACs are a fundamentally different approach to targeting proteins. Rather than blocking a receptor’s function (as SERDs do), a PROTAC recruits the cell’s own ubiquitin-proteasome system to physically degrade the target protein — in this case, the estrogen receptor. This distinction matters: existing SERDs like fulvestrant achieve only partial ER degradation and require intramuscular injection. Vepdegestrant is an oral pill that eliminates the receptor entirely, including mutant forms that have escaped traditional endocrine therapy.

The approval was based on the phase 3 VERITAC-2 trial, which enrolled 624 adults with ER+/HER2-negative advanced or metastatic breast cancer who had progressed on one to two prior lines of endocrine therapy, including a CDK4/6 inhibitor. Among the 270 patients with ESR1-mutated disease, vepdegestrant demonstrated a significant improvement in progression-free survival versus fulvestrant (HR 0.57; p<0.001). It also required co-approval of the Guardant360 CDx as a companion liquid biopsy diagnostic, cementing ctDNA-based ESR1 mutation testing as a standard-of-care necessity before initiating second-line therapy.

The safety profile was favorable — grade ≥3 treatment-emergent adverse events occurred in 23.4% of patients, with low discontinuation rates and manageable QTc signals. This gives clinicians a well-tolerated oral option in a setting that historically had very limited choices after CDK4/6 inhibitor failure.

The SERD Wave: Giredestrant and Camizestrant Push Forward

Vepdegestrant isn’t the only new agent redefining the landscape. The next-generation oral selective estrogen receptor degraders (SERDs) — which degrade the ER rather than merely blocking it — are in the final stages of their regulatory journeys.

Giredestrant (Roche/Genentech)

Giredestrant is making a push across two settings simultaneously:

In early-stage disease, the phase 3 lidERA trial showed that giredestrant reduced the risk of invasive disease recurrence or death by 30% versus standard endocrine therapy (HR 0.70; p=0.0014), with a 3-year invasive disease-free survival rate of 92.4% compared to 89.6% with standard of care. The FDA accepted the NDA under Priority Review in June 2026, with a decision expected by November 30, 2026. If approved, it would represent the first major advance in adjuvant endocrine therapy for early-stage ER+ breast cancer in decades.

In advanced ESR1-mutated disease, the phase 3 evERA trial showed giredestrant plus everolimus dramatically improved PFS versus endocrine therapy plus everolimus — with a hazard ratio of 0.38 in the ESR1-mutated subgroup. The FDA has accepted this NDA with a decision expected December 18, 2026. If approved, it would be the first all-oral SERD combination in the post-CDK4/6 inhibitor setting.

Camizestrant (AstraZeneca)

Camizestrant distinguishes itself as a next-generation oral SERD and complete ER antagonist. The SERENA-6 trial introduced a provocative new concept: rather than waiting for disease progression, patients on first-line AI + CDK4/6 inhibitor therapy underwent ctDNA monitoring every 2–3 months. When an ESR1 mutation was detected in circulating tumor DNA — before any clinical or radiographic progression — patients were switched to camizestrant while staying on the CDK4/6 inhibitor. This early-switch strategy produced a median PFS of 16.6 months in the camizestrant arm, signaling that proactive molecular surveillance may change how we sequence therapy entirely. The FDA advisory committee vote was 3–6 against; the regulatory path is still being navigated, though the NDA remains active with additional data under review.

Antibody-Drug Conjugates Enter the ER+ Arena

Traditionally the domain of HER2+ and triple-negative breast cancer, antibody-drug conjugates (ADCs) have now crossed into ER+/HER2-negative disease with real impact.

In January 2025, the FDA approved datopotamab deruxtecan (Dato-DXd; Datroway) for hormone receptor-positive, HER2-negative breast cancer — marking the first significant first-line advancement in over a decade for this population. ADCs work by attaching a cytotoxic payload to a tumor-targeting antibody, delivering chemotherapy with precision while sparing normal tissue. As these agents move earlier in the treatment sequence, they are increasingly being combined with endocrine therapy and CDK4/6 inhibitors in clinical trials.

Monitoring the Future: ctDNA and Liquid Biopsy as Treatment Tools

Perhaps the most philosophically significant shift in ER+ breast cancer isn’t a new drug — it’s a new relationship with time. Traditionally, oncologists responded to resistance after it became clinically apparent. The SERENA-6 approach — using circulating tumor DNA to detect emerging ESR1 mutations before progression — represents a shift toward proactive molecular surveillance.

The Guardant360 CDx companion diagnostic co-approved with vepdegestrant is a signal of this broader trend. Liquid biopsy is no longer just a research tool; it is now embedded in the regulatory and clinical workflow for ER+ breast cancer. As more trials adopt ctDNA-guided switching strategies, the window between molecular evolution and treatment adaptation will narrow — potentially preventing resistance before it becomes clinically meaningful.

The Bigger Picture: From Single Agents to Sequencing Strategies

What emerges from all of this is not just a list of new drugs — it is a new logic for how to treat ER+ breast cancer across its entire trajectory:

Early-stage disease: Oral SERDs like giredestrant may soon replace tamoxifen and aromatase inhibitors as the adjuvant standard, improving cure rates in the window where they matter most.
First-line advanced disease: CDK4/6 inhibitors plus next-generation SERDs (with ctDNA monitoring for early mutation switching) may extend first-line benefit longer.
Post-CDK4/6 progression: Biomarker-stratified second-line options now exist — vepdegestrant for ESR1-mutated disease, ADCs for broader populations — where previously choices were sparse.

The field is also increasingly asking the right questions about who benefits most. Biomarker gating, companion diagnostics, and molecular tumor boards are becoming essential infrastructure, not optional additions.

What This Means for Patients

For patients living with ER+ breast cancer, this moment carries genuine hope. The transition from injectable fulvestrant to oral therapies reduces the burden of clinic visits. The approval of the first PROTAC represents not just a new drug but a proof of concept for an entirely new pharmacological approach. And the growing use of liquid biopsy means that the cancer’s evolution can be tracked in real time — shifting the power dynamic between tumor biology and therapeutic response.

None of this erases the difficulty of a metastatic diagnosis. Overall survival data from many of these trials remain immature. But the trajectory of the field — toward precision, earlier intervention, and more options after resistance — is unmistakably forward.

Conclusion

ER+ breast cancer has historically been labeled the “favorable” subtype, but that framing has always obscured the reality of advanced and resistant disease. The science of 2025–2026 is finally catching up — not just extending survival, but rethinking the molecular architecture of resistance itself. From the first-ever PROTAC approval to oral SERDs approaching the adjuvant setting to ctDNA-guided treatment switching, the field is in genuine transformation.

At Makuku Global Research, we will continue tracking these developments with the rigor they deserve — because precision medicine only fulfills its promise when its advances reach every patient it was designed to help.

Sources: FDA.gov, Targeted Oncology, OncLive, LBBC, ESMO Breast Cancer 2026, Frontiers in Oncology, AstraZeneca, Genentech/Roche, Arvinas/Pfizer, AJMC, CancerNetwork

This article is intended for educational purposes. It does not constitute medical advice. Patients should consult their oncology team for guidance on treatment decisions.